A real-world analysis found that severe hypoglycemia and impaired awareness can reduce quality of life in continuous glucose monitoring (CGM) users. The report underscores that CGM adoption does not automatically remove patient burden if severe events and risk perception remain present. For device and digital health companies, the findings point to a need for tighter outcomes measurement beyond glycemic metrics—particularly around the lived experience of alarms, treatment behavior changes, and hypoglycemia recurrence. The study also reinforces how endpoint selection matters for market adoption: patients and payers increasingly want evidence that the technology translates into better day-to-day functioning, not only improved glucose traces.